TY - JOUR
T1 - The epidemiology and management of ameloblastomas
T2 - A European multicenter study
AU - Boffano, Paolo
AU - Cavarra, Francesco
AU - Tricarico, Gerardo
AU - Masu, Lavinia
AU - Brucoli, Matteo
AU - Ruslin, Muhammad
AU - Forouzanfar, Tymour
AU - Ridwan-Pramana, Angela
AU - Rodríguez-Santamarta, Tanía
AU - Rui Ranz, Marta
AU - de Vicente, Juan Carlos
AU - Starch- Jensen, Thomas
AU - Pechalova, Petia
AU - Pavlov, Nikolai
AU - Doykova, Iva
AU - Konstantinovic, Vitomir S.
AU - Jelovac, Drago
AU - Barrabé, Aude
AU - Louvrier, Aurélien
AU - Meyer, Christophe
AU - Tamme, Tiia
AU - Andrianov, Aleksei
AU - Dovšak, Tadej
AU - Birk, Anže
AU - Hresko, Andrii
AU - Chepurnyi, Yurii
AU - Kopchak, Andrii
AU - Snäll, Johanna
AU - Hagström, Jaana
AU - Rasmusson, Lars
AU - Rocchetti, Vincenzo
N1 - Publisher Copyright:
© 2021 European Association for Cranio-Maxillo-Facial Surgery
PY - 2021/12
Y1 - 2021/12
N2 - The present study aimed at assessing the epidemiology including demographic variables, diagnostic features, and management of ameloblastomas at several European departments of maxillofacial and oral surgery. The following data were recorded for each patient: gender, age, voluptuary habits, comorbidities, site, size, radiographic features, type, histopathological features, kind of treatment, length of hospital stay, complications, recurrence, management and complications of the recurrence. A total of 244 patients, 134 males and 110 females with ameloblastomas were included in the study. Mean age was 47.4 years. In all, 81% of lesions were found in the mandible, whereas 19% were found in the maxilla. Mean size of included ameloblastomas was 38.9 mm. The most frequently performed treatment option was enucleation plus curettage/peripheral ostectomy in 94 ameloblastomas, followed by segmental resection (60 patients), simple enucleation (46 patients), and marginal resection (40 patients). A recurrence (with a mean follow up of 5 years) was observed in 47 cases out of 244 ameloblastomas (19.3%). Segmental resection was associated with a low risk of recurrence (p = 0003), whereas enucleation plus curettage/peripheral ostectomy was associated with a high risk of recurrence (p = 0002). A multilocular radiographic appearance was associated with a high risk of recurrence (p < .05), as well as the benign solid/multicystic histologic type (p < .05). Within the limitations of the study it seems that the management of ameloblastomas will probably remain controversial even in the future. Balancing low surgical morbidity with a low recurrence rate is a difficult aim to reach.
AB - The present study aimed at assessing the epidemiology including demographic variables, diagnostic features, and management of ameloblastomas at several European departments of maxillofacial and oral surgery. The following data were recorded for each patient: gender, age, voluptuary habits, comorbidities, site, size, radiographic features, type, histopathological features, kind of treatment, length of hospital stay, complications, recurrence, management and complications of the recurrence. A total of 244 patients, 134 males and 110 females with ameloblastomas were included in the study. Mean age was 47.4 years. In all, 81% of lesions were found in the mandible, whereas 19% were found in the maxilla. Mean size of included ameloblastomas was 38.9 mm. The most frequently performed treatment option was enucleation plus curettage/peripheral ostectomy in 94 ameloblastomas, followed by segmental resection (60 patients), simple enucleation (46 patients), and marginal resection (40 patients). A recurrence (with a mean follow up of 5 years) was observed in 47 cases out of 244 ameloblastomas (19.3%). Segmental resection was associated with a low risk of recurrence (p = 0003), whereas enucleation plus curettage/peripheral ostectomy was associated with a high risk of recurrence (p = 0002). A multilocular radiographic appearance was associated with a high risk of recurrence (p < .05), as well as the benign solid/multicystic histologic type (p < .05). Within the limitations of the study it seems that the management of ameloblastomas will probably remain controversial even in the future. Balancing low surgical morbidity with a low recurrence rate is a difficult aim to reach.
KW - Ameloblastoma
KW - Epidemiology
KW - Recurrence
KW - Surgery
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85115959096&partnerID=8YFLogxK
U2 - 10.1016/j.jcms.2021.09.007
DO - 10.1016/j.jcms.2021.09.007
M3 - Journal article
AN - SCOPUS:85115959096
SN - 1010-5182
VL - 49
SP - 1107
EP - 1112
JO - Journal of Cranio-Maxillofacial Surgery
JF - Journal of Cranio-Maxillofacial Surgery
IS - 12
ER -